Breaking News, Collaborations & Alliances

MorphoSys Earns Novartis Milestone

MorphoSys AG has received a milestone payment from Novartis for the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG has received a milestone payment from Novartis for the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland. The milestone is related to an agreement between the two companies for Novartis to internalize the HuCAL technology. “We are delighted to have reached this important milestone with Novartis just three years after the signature of our strategic alliance,” said Dr. Simon Moroney, chief executive officer of MorphoSy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters